VTE Care Transitions Implementation Study

For patients with venous thromboembolism (VTE), anticoagulation therapy must be sustained for at least three to six months. Therapy involves multiple providers across multiple settings. The quality of transitions during this time is crucial to ensure safe and effective patient care.

Six AMGA members are working with AMGA and an expert team of Advisors in implementation science, clinical thrombosis management, and operations to improve the quality of these care transitions for VTE patients.

Resources, tools, and preliminary findings used to help AMGA members and clinicians understand and navigate VTE care transitions will be posted below as they become available.

• NEW!!! Examples of problems occurring during care transitions for patients with VTE, interventions undertaken to address them using a novel VTE transitions improvement framework.

• A Snapshot of Venous Thromboembolism. Why VTE? Why Now? AMGA Members explain why they want to focus on VTE care transitions.

• VTE Care Transitions Brief Overview. A project brief describing the exploratory work, the gaps identified, project aims and methods that will be used to achieve project outcomes.

• VTE Care Transitions Participants. Brief profiles of the six AMGA member organizations that are participating in the study.

• VTE Care Transitions Advisors. Bios of the national clinical experts and leaders in implementation science serving as advisors.

• Improving Care Transitions in Patients with Venous Thromboembolism, a webinar featuring Laura Balsamini, Pharm.D., BCPS, Summit Health and Paige Christensen, APRN, Intermountain Healthcare, Dec. 2, 2021.

• “How are You Managing Your Patients with Venous Thromboembolism?” Article in AMGA’s Group Practice Journal, describing three roundtables conducted with experts from 12 high-performing health systems on transitional care for patients with VTE. March 2021.